Navigation Links
Hospira's Biosimilar Epoetin Retacrit(TM) Receives Positive Opinion Recommending EU Approval
Date:10/18/2007

- Approval and Launch of Hospira's First Similar Biologic Expected by Early

2008 -

LAKE FOREST, Ill., Oct. 19 /PRNewswire-FirstCall/ -- Hospira (NYSE: HSP), a leading global hospital products company, announced today that it has received a "positive opinion" recommending European Union (EU) approval for Retacrit (epoetin zeta), a treatment for anemia associated with chronic renal failure and chemotherapy-induced anemia. Retacrit is a similar biologic -- often referred to as a "biosimilar" in Europe or "biogeneric" in the United States -- to epoetin alfa.

The Committee for Medicinal Products for Human Use (CHMP) issued the positive opinion; and the European Commission, which approves pharmaceuticals, usually follows CHMP recommendations. Hospira expects EU approval for Retacrit in late 2007. The company plans to launch the product -- which will be Hospira's first marketed similar biologic -- in various EU countries beginning in early 2008.

"As the world leader in generic injectables, Hospira is ready to bring high-quality, lower-cost similar biologics to patients. We are pleased to have crossed this milestone for this important medication," says Michael Kotsanis, president, Europe, Middle East and Africa, Hospira. "Similar biologics like Retacrit can help provide safe, effective patient care while helping to reduce global healthcare costs."

In late 2006 Hospira; STADA Arzneimittel AG; and BIOCEUTICALS Arzneimittel AG, a STADA-initiated company, announced development, manufacturing and distribution agreements for epoetin zeta. Under these agreements, Hospira obtained exclusive distribution rights for the product in countries including the United States and much of Europe, with the exception of Germany, where Hospira and STADA will both market the product. The epoetin zeta project is being pursued through BIOCEUTICALS. STADA controlled the development process and conducted the approval process on behalf o
'/>"/>

SOURCE Hospira, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Medical College receives $377K to study brain disease
2. Lucigen receives $750K grant to boost biofuel yields
3. Medical College receives $1.4M cancer grant
4. Wisconsin biotech firm receives $107K NIH grant
5. InvivoSciences receives NIH grant for heart technology
6. Medical College receives $11 million grant to study high blood pressure
7. Madison business receives $115,000 of new state biofuels funding
8. Superior receives funds for technical training
9. UWM receives state funding for plastics research
10. GEs Centricity EHR receives federal certification
11. WHIE receives state eHealth Initiative contract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014 /PRNewswire-iReach/ -- Tute Genomics, the ... announced an agreement with Lineagen, Inc., to ... NextStep Dx PLUS.  Lineagen, focused on ... disorders, currently offers FirstStep Dx PLUS, ... used by healthcare providers as a first-line ...
(Date:7/10/2014)... April 15, 2014 -- According to the International ... nuclear security comes from terrorists acquiring sufficient quantities ... construct a crude nuclear explosive device. The IAEA ... trafficking have involved gram-level quantities, which can be ... According to a new study appearing this week ...
(Date:7/10/2014)... in the journal PNAS (Proceedings of the National ... day and sleep deprivation have a significant effect on ... at the best time of day to test for ... administering medicines effectively. , Researchers from the University of ... the links between sleep deprivation, body clock disruption and ...
(Date:7/10/2014)... The lithium-ion batteries that power our laptops and ... on a single charge with the help of a ... material to replace the graphite traditionally used in one ... 10 times the energy storage capacity of graphite. A ... electrode was published today in Nature Communications . ...
Breaking Biology Technology:Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Sensitive detection method may help impede illicit nuclear trafficking 2Time of day crucial to accurately test for diseases, new research finds 2Silicon sponge improves lithium-ion battery performance 2Silicon sponge improves lithium-ion battery performance 3
... weeks back, we took a look at the results of the ... that time, we saw that the Midwest had two states in the ... the top 20 states. I promised to circle back with you to ... the Midwest fared in this ranking. , ,The NIH falls under ...
... slowly getting over its shyness about asking for federal ... business executives is learning more about how ... Business Technology Transfer Conference at the Hilton Milwaukee ... programs, one (SBIR) designed to foster small business innovation, ...
... - Angel and venture investors have fewer secrets ... dispense some advice to early-stage executives during the National ... with scientific ties to the University of Wisconsin-Madison ... their products have a sustainable market advantage, and what ...
Cached Biology Technology:Midwest colleges strong contenders for NIH funds 2Midwest colleges strong contenders for NIH funds 3Midwest colleges strong contenders for NIH funds 4Midwest colleges strong contenders for NIH funds 5Wisconsin firms urged to pursue federal SBIR dollars 2Wisconsin firms urged to pursue federal SBIR dollars 3Early-stage executives hear from investors 2Early-stage executives hear from investors 3
(Date:7/11/2014)... mesenchymal stem cells can stimulate neurogenesis in the brain ... (AD) and improve tissue and function injury under the ... the therapeutic effect of adipose-derived stem cells (ADSCs) transplantation ... oxidative injury and neurogenesis in the brain of AD ... Life Sciences, Tsinghua University, China transplanted ADSCs into the ...
(Date:7/11/2014)... toxins to study the proteins that let nerve cells ... have stumbled upon a biological tactic that may offer ... in a safe and environmentally responsible way. , ... for one species and harmless for a closely related ... pests without harming beneficial species like bees. A summary ...
(Date:7/10/2014)... BEDFORD, Mass. , June 30, 2014  Aware, ... of biometrics software and services, previously announced on June ... a special cash dividend of $1.75 per share, or ... record date of July 10, 2014 and a payment ... notified by NASDAQ that it had set an ex-dividend ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2
... This release is available in French . ... the Minister of Industry, on behalf of the Honourable ... the Natural Sciences and Engineering Research Council of Canada ... announced that Nobel Laureate John C. Polanyi is the ...
... have a sizeable biofuels industry based primarily on local ... and new conversion technologies are used, according to a ... Northwest National Laboratory. It will be difficult ... based on todays land use practices with currently available ...
... WINSTON-SALEM, N.C. A small group of patients with ... veins with an injectable microfoam experienced no neurological, visual ... according to preliminary results from a phase II trial. ... Washington, D.C., at the annual scientific meeting of the ...
Cached Biology News:Dr. John Polanyi wins Canada's most prestigious science award 2Key to using local resources for biomass may include waste 2Key to using local resources for biomass may include waste 3Improved foam for varicose veins found to be safe in preliminary results from phase II trial 2
Dual-bay Dyad thermal cycler chassis, does not include the Alpha units (requires 2)...
... dual-bay DNA Engine Dyad thermal cycler ... amplification (PCR). The chassis accommodates a ... heat-pump assemblies), which hold different types ... offers graphical programming with point-and-click navigation. ...
... Red fluorescent RNA stain is used to ... or glyoxal) agarose gels and does not ... a 302 nm transilluminator, the stain emits ... on Polaroid film or with a CCD ...
... The MitoPT kit is used in conjunction ... in culture and induce apoptosis according to your ... cells as a negative control). Once you have ... MitoPT solution to each population and incubate the ...
Biology Products: